ArticleWorld journal of surgical oncology2025
Initial oncological outcomes of nipple- and areola-sparing mastectomy in patients with breast cancer with nipple discharge.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to assess the oncological safety of nipple- and areola-sparing mastectomy (NSM) compared to mastectomy without preservation of the nipple-areola complex (NAC) in patients with breast cancer presenting with nipple discharge.
methodsClinical data were retrospectively reviewed for 93 patients who underwent NSM and 133 patients who underwent mastectomy without NAC preservation for non-metastatic breast cancer between March 2015 and August 2023 at two hospitals. All patients presented with bloody or serous nipple discharge. Clinicopathological characteristics of both groups were assessed to evaluate the oncological safety of NSM and identify prognostic factors.
resultsLocal recurrence rates and disease-free survival rates at 3 and 5 years did not differ significantly between the groups (p > 0.05). Univariate analysis identified tumor T stage, lymph node metastasis count, and histological grade as independent risk factors influencing disease-free survival and overall survival (p < 0.05). Tumors larger than 2 cm, lymph node positivity, and grade III histology were associated with an elevated risk of recurrence. Multivariate analysis further confirmed tumor T stage and lymph node metastasis count as significant risk factors for both disease-free survival and overall survival, with larger tumors and positive lymph node status linked to an increased risk of mortality.
conclusionNSM demonstrated oncological safety in this patient population. Prognostic factors significantly affecting survival outcomes included tumor T stage, lymph node metastasis count, and histological grade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.